Literature DB >> 25427164

New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation.

Tomohiro Iguchi1, Ken Shirabe, Shinichi Aishima, Huanlin Wang, Nobuhiro Fujita, Mizuki Ninomiya, Yo-ichi Yamashita, Toru Ikegami, Hideaki Uchiyama, Tomoharu Yoshizumi, Yoshinao Oda, Yoshihiko Maehara.   

Abstract

BACKGROUND: Vascular invasion of hepatocellular carcinoma (HCC) has a high incidence of recurrence after liver transplantation. Patients with microvascular invasion (MVI) show a high tumor grade; however, some show a good prognosis. This retrospective study aimed to investigate whether the degree of MVI affects prognosis after living-donor liver transplantation.
METHODS: A total of 142 patients with HCC who had undergone living-donor liver transplantation were histologically evaluated about the number of invaded vessels and the maximum number of invading carcinoma cells. Patients with MVI were classified into two subgroups: high MVI group (n = 38), which showed more than 50 carcinoma cells in the vessels, with multiple invaded vessels; and low MVI group (n = 17), which showed MVI, but not high MVI.
RESULTS: Analysis of recurrence-free survival showed that high MVI group had significantly poorer outcomes than the other groups (P < 0.001). High MVI group had significantly higher α-fetoprotein levels, des-γ-carboxy prothrombin levels, number of tumors, a larger tumor size, and a higher percentage of poorly differentiated HCC than non-MVI group. High MVI was an independent prognostic factor for recurrence-free survival (P = 0.030). Among patients exceeding the Milan criteria (n = 61), high MVI group had significantly poorer outcomes than the other groups for recurrence-free survival (P = 0.003). Patients in high MVI group had significantly higher des-γ-carboxy prothrombin levels and a larger tumor size than non-MVI group. High MVI was an independent prognostic factor for recurrence-free survival (P = 0.014).
CONCLUSION: In living-donor liver transplantation for HCC, high MVI is a novel pathologic marker for predicting prognosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25427164     DOI: 10.1097/TP.0000000000000489

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  42 in total

1.  Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma.

Authors:  Zhijun Zhu
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

Review 2.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

3.  Perioperative Allogeneic Blood Transfusion Does not Influence Patient Survival After Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Authors:  Yo-Ichi Yamashita; Hiromitsu Hayashi; Katsunori Imai; Hirohisa Okabe; Shigeki Nakagawa; Fumimasa Kitamura; Norio Uemura; Yosuke Nakao; Toshihiko Yusa; Rumi Itoyama; Takanobu Yamao; Naoki Umesaki; Tatsunori Miyata; Akira Chikamoto; Mototsugu Shimokawa; Hideo Baba
Journal:  World J Surg       Date:  2019-11       Impact factor: 3.352

4.  A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome.

Authors:  Xin Jiang; Yushuang Xu; Di Chen; Mengmeng Wang; Mengjun Qiu; Lina Xiong; Li Zhang; Honglu Yu; Zhifan Xiong
Journal:  Int J Gen Med       Date:  2022-01-07

5.  Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Dawei Chen; Shuanghai Liu; Sheng Chen; Zhaowen Wang; Zehua Wu; Kai Ma; Junwei Fan; Zhihai Peng
Journal:  Int J Clin Oncol       Date:  2016-07-01       Impact factor: 3.402

6.  Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).

Authors:  Jian Zhou; Hui-Chuan Sun; Zheng Wang; Wen-Ming Cong; Jian-Hua Wang; Meng-Su Zeng; Jia-Mei Yang; Ping Bie; Lian-Xin Liu; Tian-Fu Wen; Guo-Hong Han; Mao-Qiang Wang; Rui-Bao Liu; Li-Gong Lu; Zheng-Gang Ren; Min-Shan Chen; Zhao-Chong Zeng; Ping Liang; Chang-Hong Liang; Min Chen; Fu-Hua Yan; Wen-Ping Wang; Yuan Ji; Wen-Wu Cheng; Chao-Liu Dai; Wei-Dong Jia; Ya-Ming Li; Ye-Xiong Li; Jun Liang; Tian-Shu Liu; Guo-Yue Lv; Yi-Lei Mao; Wei-Xin Ren; Hong-Cheng Shi; Wen-Tao Wang; Xiao-Ying Wang; Bao-Cai Xing; Jian-Ming Xu; Jian-Yong Yang; Ye-Fa Yang; Sheng-Long Ye; Zheng-Yu Yin; Bo-Heng Zhang; Shui-Jun Zhang; Wei-Ping Zhou; Ji-Ye Zhu; Rong Liu; Ying-Hong Shi; Yong-Sheng Xiao; Zhi Dai; Gao-Jun Teng; Jian-Qiang Cai; Wei-Lin Wang; Jia-Hong Dong; Qiang Li; Feng Shen; Shu-Kui Qin; Jia Fan
Journal:  Liver Cancer       Date:  2018-06-14       Impact factor: 11.740

7.  Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Authors:  Jian Zhou; Huichuan Sun; Zheng Wang; Wenming Cong; Jianhua Wang; Mengsu Zeng; Weiping Zhou; Ping Bie; Lianxin Liu; Tianfu Wen; Guohong Han; Maoqiang Wang; Ruibao Liu; Ligong Lu; Zhengang Ren; Minshan Chen; Zhaochong Zeng; Ping Liang; Changhong Liang; Min Chen; Fuhua Yan; Wenping Wang; Yuan Ji; Jingping Yun; Dingfang Cai; Yongjun Chen; Wenwu Cheng; Shuqun Cheng; Chaoliu Dai; Wenzhi Guo; Baojin Hua; Xiaowu Huang; Weidong Jia; Yaming Li; Yexiong Li; Jun Liang; Tianshu Liu; Guoyue Lv; Yilei Mao; Tao Peng; Weixin Ren; Hongcheng Shi; Guoming Shi; Kaishan Tao; Wentao Wang; Xiaoying Wang; Zhiming Wang; Bangde Xiang; Baocai Xing; Jianming Xu; Jiamei Yang; Jianyong Yang; Yefa Yang; Yunke Yang; Shenglong Ye; Zhengyu Yin; Bixiang Zhang; Boheng Zhang; Leida Zhang; Shuijun Zhang; Ti Zhang; Yongfu Zhao; Honggang Zheng; Jiye Zhu; Kangshun Zhu; Rong Liu; Yinghong Shi; Yongsheng Xiao; Zhi Dai; Gaojun Teng; Jianqiang Cai; Weilin Wang; Xiujun Cai; Qiang Li; Feng Shen; Shukui Qin; Jiahong Dong; Jia Fan
Journal:  Liver Cancer       Date:  2020-11-11       Impact factor: 11.740

8.  Microscopic vascular invasion by hepatocellular carcinoma in liver transplant patients.

Authors:  Brian I Carr; Volkan Ince; Harika Gozukara Bag; Veysel Ersan; Sertac Usta; Sezai Yilmaz
Journal:  Clin Pract (Lond)       Date:  2020

9.  Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Deep Learning: A Multi-Center and Prospective Validation Study.

Authors:  Jingwei Wei; Hanyu Jiang; Mengsu Zeng; Meiyun Wang; Meng Niu; Dongsheng Gu; Huanhuan Chong; Yanyan Zhang; Fangfang Fu; Mu Zhou; Jie Chen; Fudong Lyv; Hong Wei; Mustafa R Bashir; Bin Song; Hongjun Li; Jie Tian
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

10.  Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma.

Authors:  Joonho Jeong; Jung Gu Park; Kwang Ill Seo; Ji Hyun Ahn; Jae Chun Park; Byung Cheol Yun; Sang Uk Lee; Jin Wook Lee; Jong Hyouk Yun
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.